Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of precision genetic medicines to treat rare neuromuscular diseases, including Duchenne muscular dystrophy. The company develops gene therapy, RNA-targeted and gene-editing therapies and has a marketed portfolio and multiple pipeline programs.
Layoff history
EMPLOYEES AFFECTED PER QUARTER · HOVER FOR DETAILS
Layoff timeline
2 EVENTSSarepta Therapeutics, Inc. announced it laid off more than one-third of its workforce, approximately 500 employees, as a drastic cost-cutting measure after two teenage patient deaths prompted restrictions on its Duchenne gene therapy. The company said the cuts and a shift in R&D — including pausing several limb-girdle muscular dystrophy gene therapy programs — will save about $400 million per year, lower operating expenses, and preserve cash flow to maintain access to an existing loan agreement. The move was disclosed in an SEC filing that also noted promotions and salary increases for three top executives. The layoffs are presented as an immediate reduction in force tied to safety-related commercial and development setbacks.
Stories from here
No one has shared a story from Sarepta yet. Went through a layoff here? Your experience helps others feel less alone.
Share your story →Get alerts for Sarepta
We'll email you the moment a new layoff is reported here.